Market Access Barriers Deterring New China R&D Investment: AmCham
This article was originally published in PharmAsia News
Executive Summary
Market access barriers are deterring 80% of US R&D-intensive industries, including pharma, from investing further in China, and many are pessimistic about the future regulatory environment in the country, says a just released business climate survey.
You may also be interested in...
As Trump Meets Xi, Executives Face Changing Dynamics In China
China is aggressively driving up life sciences innovations, leading the charge in technologies including gene editing and genome testing, prompting executives to take a fresh approach.
2016 Review: Pricing, R&D Issues Dominate China Commercial Arena
2016 was again another busy year on the commercial front in China, with market changes, new regulations, and ongoing pricing pressures all affecting the pharma sector. Meanwhile, the push for licensing deals, innovation, and international expansion continued apace.
Medtechs Must Reflect On China Localization Policies As VBP Expands
China continues to roll out volume-based procurement for medical devices and pharma products and companies should plan their strategies accordingly, advises EY Parthenon’s Hua Su.